Qinhao Pharmaceutical B round -financing signing core pipeline second phase of clinical clinical will be launched soon

At the root of the park, the development of the enterprise started accelerated. On July 22, Qinhao Pharmaceutical (Suzhou) Co., Ltd. held a round -financing signing ceremony, and the core pipeline II clinical was about to start. In the future, Qinhao Pharmaceutical will continue to focus on the research and development of the world's leading new anti -tumor anti -tumor drugs, accelerate the clinical and listing process, and let China's innovative drugs embrace the global market. Ni Qian, a member of the Party Working Committee of the Suzhou Industrial Park and deputy director of the Management Committee, attended the event.

As a key innovative biomedical enterprise cultivated in the park, since the settlement of the park in 2014, Qinhao Pharmaceutical has deeply cultivated the research and development of small molecular drugs, and established three major R & D centers including new drug design and development centers, new drug screening and evaluation centers, and clinical development centers. Including structural biology, transformation of medicine, patent medicine evaluation and other combination technology platforms, formed a three -generation product pipeline layout with more than ten high -value targeting antitumor drugs, covering a variety of tumor types, and the completion of Shanghai -Asia Biocences. $ 282 million in overseas rights transfer transactions. This year, the enterprise has made up its strength, completed the 300 million yuan B financing, and promoted the core product KRASG12C inhibitor GH35 project to the clinical clinical of Phase II.

At the event site, Qinhao Pharmaceutical and Series B financing institutions led the capital to receive capital signing, and signed a contract with the Phasentery clinical strategic partner of GH35II. "Qinhao has a variety of products in the RAS/MPAK signaling channel and deployed in -depth. We will accelerate the process of clinical advancement and listing of the product and benefit patients with global patients." With support, the enterprise develops rapidly. "We will take root in the park, deeply cultivate the park, continue to increase investment, build a global headquarters and international and high -standard R & D centers, attract global talents, and contribute to the" No. 1 industry '. "

Biomedical is the "No. 1 Industry" created by the park. At present, more than 2,150 related enterprises have been gathered, and 24 listed companies have been cultivated. In 2021, the output value was 117.7 billion yuan. The three special competitiveness of industry, talent, and technology ranks first in the country. In the field of new drug research and development, a total of 66 projects have received special support for the national "major new drug creation". The full -industry chain public service platform system covers basic research, drug research and development, clinical trials, large -scale production and listing and sales.

At present, the biomedical industry of the park has entered a period of accelerated growth and the transformation period of innovation results. It has formed high -quality projects. First -class talents have accelerated, and the vibrant industrial innovation clusters. Ni Qian said that the park will continue to improve policies, strengthen platforms, and provide excellent services, create a first -class industrial ecology and business environment, take the opportunity to build a national biopharmaceutical technology innovation center, and make every effort to build international first -class biomedical innovation sources and world -class sources, world -class levels The core area of ​​the biomedical industry landmark.

Editor Gu Yafang Photography Shen Xueyi

July 22, 2022

- END -